BeiGene Signs China CMO Deal with Boehringer Ingelheim
September 03, 2014 at 06:24 AM EDT
BeiGene, a Beijing innovative drug development company, signed a contract manufacturing agreement with Boehringer Ingelheim that calls for BI to produce BeiGene's drugs at its Shanghai biopharma facility. BI's $82 million plant, located in the Zhangjiang Hi-Tech Park, is currently under construction and should be complete next year. Last week, in a separate announcement, BeiGene said its third molecule had started a clinical trial, underscoring its need for a CMO partner. More details.... Share this with colleagues: // // />